NewsSource: EClinCloud

New Scale Assessment Technologies in Psychiatric and Psychological Clinical Research: eCOA

5 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: eClinCloud.


Click the blue text above to follow us

Article image



From August 24 to 27, 2021, the "Training Series on Clinical Research Technologies and Capabilities for Psychiatric and Psychological Disorders" was successfully held. Dr. Qin Long, CEO of EClinCloud, was invited to give a keynote presentation titled "New Scale Assessment Technologies in Psychiatric and Psychological Clinical Research." He gave a comprehensive overview of what are currently three new technologies in scale assessment: eCOA, rater training, and blinded data analysis, along with case studies demonstrating how these new technologies help clinical research.


We will introduce these three new technologies in a three-part series; this article covers Part 1: eCOA.



Article image


Electronic clinical outcome assessment (eCOA) is an electronic tool that describes or reflects how a patient feels, functions, or survives in a clinical trial. Globally, eCOA is increasingly being adopted on a large scale. In China, national policies also encourage the use of electronic assessment methods to reduce participant burden.

Many people wonder what the exact relationship is between eCOA and ePRO. In fact, ePRO is one of the types included under eCOA, and it is completed by the patient. For a detailed introduction to COA, please see our previous article: Copyright and Licensing Considerations When Using Existing COA Scales in Clinical Trials.

Article image


Within eCOA, ePRO consists of firsthand data coming directly from the patient rather than transcribed data. Direct data capture and transmission help ensure the timeliness and authenticity of records as well as study quality, while reducing the recording workload for research staff and minimizing data transcription errors. As a result, ePRO is currently the most widely used.

On the regulatory front, in 2017, the U.S. FDA released its plan for developing guidance on patient-focused drug development. In November 2020, ICH adopted the Patient Focused Drug Development (PFDD) topic paper to develop guidance on methodologies for collecting and analyzing patient input and on tool development. On July 2, 2021, the Center for Drug Evaluation (CDE) released the "Guiding Principles for Clinical Value-Oriented Clinical Development of Antitumor Drugs (Draft for Comment)", aiming to implement a development philosophy guided by clinical value and centered on patient needs.

The guiding principles devote substantial space to stating that antitumor drug development should be carried out in accordance with a patient-needs-centered philosophy—understanding what patients need and listening to the patient voice. Previously, patients' diseases were evaluated from the third-party perspectives of investigators, assessment bodies, or regulators, while the physical, psychological, and personal life impacts on patients, as well as the burden of treatment on patients, were often overlooked. The guidance also explicitly states that regarding "selection of clinical endpoints," applicants are encouraged to develop multiple assessment approaches, such as electronic PRO data collection systems (ePRO), to reduce the assessment burden on participants.

Article image


Article image


eCOA can be implemented across different devices, including smartphones, tablets, and computers. Mobile interfaces may also be divided into clinician-facing and patient-facing versions, as clinician entry is sometimes required, particularly for psychiatric scales. If it is only a diary, patients may simply download an app on their smartphone to enter data.

Protocol design is very convenient: simply drag and drop the required questions into place with a what-you-see-is-what-you-get interface.

For standardized scales, we provide an extensive library of standard scales as well as translated and validated versions in different languages, all ready to be referenced directly.


Complex edit checks are supported. Items within a scale often have interdependencies that experienced raters or people familiar with the scale will recognize. In these cases, using clinical outcome assessment (COA) electronically is very convenient: once these logic rules are built in, any potential error on an item can be seen immediately during data entry.

On both the sponsor and study site portals, various types of data can be viewed in real time. For problematic data, issues can be identified and corrected promptly. For data modifications, we follow a strict DCF process to ensure the compliance and validity of changes, support better risk management, and further improve data quality.

Once data are entered, they can also be viewed across different dimensions to obtain a more accurate result. Reports can also be customized by role, allowing personnel in different functions to view different reports in real time.



Article image


Adopting this electronic approach ultimately accelerates trial timelines, because data cleaning is performed continuously throughout the trial. Once the last patient's last visit is entered, database lock can be completed very quickly, far outpacing paper-based methods. Moreover, electronic records do not need physical archiving or mailing—the database can be downloaded, packaged, and sent to study sites in encrypted form.



The Value of EClinCloud eCOA


  • Real-time data monitoring to improve compliance throughout the trial;

  • Support for offline scale completion;

  • Reminders for subjects to complete data entry—for example, when the protocol requires patients to enter certain data during a specific time window, reminders can be configured in the app;

  • Real-time access to data for sponsors, CROs, and study sites through multi-dimensional reporting tools;

  • Rapid deployment when the protocol changes during a trial—because our eCOA is cloud-deployed, updates only require publishing a new version online, which is much more convenient and faster than paper;

  • Significantly shortened database lock times, accelerating trial timelines;

  • Direct data entry via smartphone, reducing subjects' travel burden and time costs to some extent while improving subject adherence and satisfaction;

  • Traceable trial data, following the requirements of 21 CFR Part 11;

  • Enabling study sites to focus more on data such as subject safety and trial compliance, reducing site burden.


Whether from the evolution of clinical drug development
or from national policy,
we see a direction for future drug development:
the principle of being guided by clinical value and centered on patient needs
will run through nearly all drug development.
We believe eCOA technology will see increasing adoption in the future.

Article image


EClinCloud

With the mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a healthcare and life sciences technology company rooted in China and serving the world. Through EClinCloud's seamlessly integrated end-to-end platform (including CTMS, EDC, eTMF, eCOA, eConsent, RTSM, and other solutions, along with consulting services such as scale management, linguistic validation, and study design) and precision medical evaluation systems across therapeutic areas (oncology, neurology, cardiology, pulmonology, dermatology, etc.), we are building a globally leading, "patient-centric," integrated SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the launch of drugs/devices, and benefit countless patients.
Article image


Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.